Singapore markets closed

HROW Oct 2024 16.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.1100-1.0400 (-48.37%)
At close: 01:53PM EDT
Full screen
Previous close2.1500
Open1.1000
Bid0.1000
Ask1.5500
Strike16.00
Expiry date2024-10-18
Day's range1.0100 - 1.1700
Contract rangeN/A
Volume10
Open interest356
  • Business Wire

    Harrow Provides TRIESENCE® Relaunch Update

    NASHVILLE, Tenn., June 20, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA‑approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsiv

  • Business Wire

    Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

    NASHVILLE, Tenn., June 06, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingually using Catalent Inc.’s proprietary fast‑dissolving Zy

  • Business Wire

    Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study

    NASHVILLE, Tenn., June 05, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE‑2 study, re